Drug delivery systems for hormone therapy

Journal of Controlled Release

Volumn 112, Issue 1, 2006, Pages 1-14

  Yoo, Jin Wook ^a   Lee, Chi H ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Delivery systems; Drug formulations; Estrogens; Hormone therapy; Progesterones

Indexed keywords

DELIVERY SYSTEMS; DRUG FORMULATIONS; ESTROGENS; HORMONE THERAPY (HT); PROGESTERONES;

CLINICAL LABORATORIES; HEALTH CARE; HEALTH RISKS; HORMONES; OPTIMIZATION; PATIENT TREATMENT;

DRUG THERAPY;

AYGENSTIN; CLOMIFENE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DEPO SUBQ PROVERA 104; DYDROGESTERONE; ESCLIM; ESTRADIOL; ESTRADIOL CIPIONATE; ESTRADIOL CIPIONATE PLUS TESTOSTERONE CIPIONATE; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; ESTRIOL; ESTRIOL SUCCINATE; ESTROGEN; EVAMIST; FEMHRT; FEMRING; GESTAGEN; LASOFOXIFENE; MEDROXYPROGESTERONE ACETATE; MINERA; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTREL; ORTHO PREFEST; PHYTOESTROGEN; PIPERAZINE ESTRONE SULFATE; PREGNANE DERIVATIVE; PREMPHASE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TESTOSTERONE; TIBOLONE; TOREMIFENE; UNCLASSIFIED DRUG; WAY 1699;

AMENORRHEA; BLEEDING; BREAST CANCER; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG IMPLANT; DRUG MIXTURE; DRUG POTENCY; EMULSION; ENDOMETRIUM CANCER; GALLBLADDER DISEASE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERTRIGLYCERIDEMIA; INJECTION; INJECTION SITE PAIN; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL SOCIETY; MENOPAUSAL SYNDROME; MENOPAUSE; OVARY CANCER; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK; STROKE; TABLET; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; UTERUS CANCER; VAGINA RING; VAGINAL DRYNESS; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; CEREBROVASCULAR ACCIDENT; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HORMONES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTINS; STROKE; THROMBOEMBOLISM;

EID: 33645776260     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.01.021     Document Type: Review

References (138)

1. Schneider H.P. The view of The International Menopause Society on the Women's Health Initiative. Climacteric 5 (2002) 211-216
2. Cardozo L., Bachmann G., McClish D., Fonda D., and Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet. Gynecol. 92 (1998) 722-727
3. Seeman E. Osteoporosis: trials and tribulations. Am. J. Med. 103 (1997) 74S-87S (discussion 87S-89S)
4. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
5. Mazzuoli G., Acca M., Pisani D., Diacinti D., Scarda A., Scarnecchia L., Pacitti M.T., D'Erasmo E., Minisola S., Bianchi G., and Manfredi G. Annual skeletal balance and metabolic bone marker changes in healthy early postmenopausal women: results of a prospective study. Bone 26 (2000) 381-386
6. O'Connell M.B. Pharmacokinetic and pharmacologic variation between different estrogen products. J. Clin. Pharmacol. 35 (1995) 18S-24S
7. Turgeon J.L., McDonnell D.P., Martin K.A., and Wise P.M. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304 (2004) 1269-1273
8. Ness J., Aronow W.S., Newkirk E., and McDanel D. Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial. J. Gerontol. A. Biol. Sci. Med. Sci. 60 (2005) 460-462
9. Davis S.R., Dinatale I., Rivera-Woll L., and Davison S. Postmenopausal hormone therapy: from monkey glands to transdermal patches. J. Endocrinol. 185 (2005) 207-222
10. Stanczyk F.Z. Pharmacokinetics of progesterone administered by the oral and parenteral routes. J. Reprod. Med. 44 (1999) 141-147
11. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 9 (2002) 6-15
12. Hall J.M., Couse J.F., and Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276 (2001) 36869-36872
13. Kuhl H. Mechanisms of sex steroids. Future developments. Maturitas 47 (2004) 285-291
14. Vegeto E., Belcredito S., Etteri S., Ghisletti S., Brusadelli A., Meda C., Krust A., Dupont S., Ciana P., Chambon P., and Maggi A. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9614-9619
15. Manolagas S.C., Kousteni S., and Jilka R.L. Sex steroids and bone. Recent Prog. Horm. Res. 57 (2002) 385-409
16. Losel R.M., Falkenstein E., Feuring M., Schultz A., Tillmann H.C., Rossol-Haseroth K., and Wehling M. Nongenomic steroid action: controversies, questions, and answers. Physiol. Rev. 83 (2003) 965-1016
17. Mendelsohn M.E. Genomic and nongenomic effects of estrogen in the vasculature. Am. J. Cardiol. 90 (2002) 3F-6F
18. Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., and Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9 (1990) 1603-1614
19. Oettel M., Elger W., Gräser T., Holz C., Lähteenmäki P., and Patchev V. What is past is prologue: estrogen/progestin replacement tomorrow. Gynecol. Endocrinol. 10 (2001) 68-90
20. McDonnell D.P., Connor C.E., Wijayaratne A., Chang C.Y., and Norris J.D. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog. Horm. Res. 57 (2002) 295-316
21. Weisenburger W.P., Hagler A.R., and Tassinari M.S. Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats. Birth Defects Res. B. Dev. Reprod. Toxicol. 71 (2004) 171-184
22. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Gluer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., and Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
23. Labrie F., El-Alfy M., Berger L., Labrie C., Martel C., Belanger A., Candas B., and Pelletier G. The combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health?. Endocrinology 144 (2003) 4700-4706
24. Palmieri C., Lam E.W., Vigushin D., and Coombes R.C. Value of SERMs in postmenopausal women. Lancet 363 (2004) 1477-1478
25. Chadwick C.C., Chippari S., Matelan E., Borges-Marcucci L., Eckert A.M., Keith Jr. J.C., Albert L.M., Leathurby Y., Harris H.A., Bhat R.A., Ashwell M., Trybulski E., Winneker R.C., Adelman S.J., Steffan R.J., and Harnish D.C. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2543-2548
26. Moore R.A. Livial: a review of clinical studies. Br. J. Obstet. Gynaecol. 106 Suppl 19 (1999) 1-21
27. Hammar M., Christau S., Nathorst-Böös J., Rud T., and Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptom. BJOG 105 (1998) 904-911
28. Kloosterboer H.J. Tibolone: a steroid with a tissue-specific mode of action. J. Steroid. Biochem. Mol. Biol. 76 (2001) 231-238
29. Gompel A., Siromachkova M., Lombet A., Kloosterboer H.J., and Rostene W. Tibolone actions on normal and breast cancer cells. Eur. J. Cancer 36 Suppl 4 (2000) S76-S77
30. Beral V., Bull D., and Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
31. Neves-e-Castro M., Samsioe G., Doren M., and O.S. S. Results from WHI and HERS II-implications for women and the prescriber of HRT. Maturitas 42 (2002) 255-258
32. Tanna N. Hormone replacement therapy (2): risks and benefits. Pharm. J. 271 (2003) 646-648
33. Stevenson J.C. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 51 (2005) 113-126
34. Tsai K.S., Yen M.L., Pan H.A., Wu M.H., Cheng W.C., Hsu S.H., Yen B.L., and Huang K.E. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos. Int. 12 (2001) 1020-1025
35. Towler B.P., Irwig L., Glasziou P., Weller D., and Kewenter J. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst. Rev. (2000) CD001216
36. Hulley S., Furberg C., Barrett-Connor E., Cauley J., Grady D., Haskell W., Knopp R., Lowery M., Satterfield S., Schrott H., Vittinghoff E., and Hunninghake D. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 58-66
37. Nanda K., Bastian L.A., Hasselblad V., and Simel D.L. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet. Gynecol. 93 (1999) 880-888
38. Grodstein F., and Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog. Cardiovasc. Dis. 38 (1995) 199-210
39. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., Speizer F.E., and Hennekens C.H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335 (1996) 453-461
40. Stampfer M.J., and Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20 (1991) 47-63
41. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., and Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
42. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., and Hennekens C.H. Menopause and the risk of coronary heart disease in women. N. Engl. J. Med. 316 (1987) 1105-1110
43. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
44. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 (1997) 1047-1059
45. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., Bonds D., Brunner R., Brzyski R., Caan B., Chlebowski R., Curb D., Gass M., Hays J., Heiss G., Hendrix S., Howard B.V., Hsia J., Hubbell A., Jackson R., Johnson K.C., Judd H., Kotchen J.M., Kuller L., LaCroix A.Z., Lane D., Langer R.D., Lasser N., Lewis C.E., Manson J., Margolis K., Ockene J., O'Sullivan M.J., Phillips L., Prentice R.L., Ritenbaugh C., Robbins J., Rossouw J.E., Sarto G., Stefanick M.L., Van Horn L., Wactawski-Wende J., Wallace R., and Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
46. Ross R.K., Paganini-Hill A., Wan P.C., and Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92 (2000) 328-332
47. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., and Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283 (2000) 485-491
48. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 273 (1995) 199-208
49. Beresford S.A., Weiss N.S., Voigt L.F., and McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349 (1997) 458-461
50. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., and Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348 (1996) 977-980
51. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., and Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA 288 (2002) 872-881
52. Scarabin P.Y., Oger E., and Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362 (2003) 428-432
53. Lacey Jr. J.V., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., Schatzkin A., and Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 (2002) 334-341
54. Vehkavaara S., Hakala-Ala-Pietila T., Virkamaki A., Bergholm R., Ehnholm C., Hovatta O., Taskinen M.R., and Yki-Jarvinen H. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 102 (2000) 2687-2693
55. Longcope C., Gorbach S., Goldin B., Woods M., Dwyer J., and Warram J. The metabolism of estradiol; oral compared to intravenous administration. J. Steroid. Biochem. 23 (1985) 1065-1070
56. Crook D., and Stevenson J.C. Transdermal hormone replacement therapy, serum lipids and lipoproteins. Br. J. Clin. Pract. Suppl. 86 (1996) 17-21
57. Wattanakumtornkul S., Pinto A.B., and Williams D.B. Intranasal hormone replacement therapy. Menopause 10 (2003) 88-98
58. Meyer W.R., Costello N., Straneva P., West S., Copel K., and Girdler S. Effect of low-dose estrogen on hemodynamic response to stress. Fertil. Steril. 75 (2001) 394-399
59. Smith N.L., Heckbert S.R., Lemaitre R.N., Reiner A.P., Lumley T., Weiss N.S., Larson E.B., Rosendaal F.R., and Psaty B.M. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292 (2004) 1581-1587
60. Yen S.S., Martin P.L., Burnier A.M., Czekala N.M., Greaney Jr. M.O., and Callantine M.R. Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17beta-estradiol in postmenopausal women. J. Clin. Endocrinol. Metab. 40 (1975) 518-521
61. Callantine M.R., Martin P.L., Bolding O.T., Warner P.O., and Greaney Jr. M.O. Micronized 17 beta-estradiol for oral estrogen therapy in menopausal women. Obstet. Gynecol. 46 (1975) 37-41
62. Veeranarapanich S., Bunyavejchevin S., and Lumlertkittikul S. Serum estradiol level in Thai surgical menopausal women receiving oral micronized 17 beta-estradiol 1 mg. J. Med. Assoc. Thai. 87 Suppl 2 (2004) S1-S4
63. Prestwood K.M., Kenny A.M., Unson C., and Kulldorff M. The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 85 (2000) 4462-4469
64. Alexandersen P., Byrjalsen I., and Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. BJOG 107 (2000) 356-364
65. Zhao L., Chen S., and Brinton R.D. An estrogen replacement therapy containing nine synthetic plant-based conjugated estrogens promotes neuronal survival. Exp. Biol. Med. (Maywood) 228 (2003) 823-835
66. Muneyyirci-Delale O., and Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int. J. Fert. Women's Med. 43 (1998) 24-27
67. Gelfand M.M., Moreau M., Ayotte N.J., Hilditch J.R., Wong B.A., and Lau C.Y. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. Menopause 10 (2003) 29-36
68. Burnier A.M., Martin P.L., Yen S.S., and Brooks P. Sublingual absorption of micronized 17beta-estradiol. Am. J. Obstet. Gynecol. 140 (1981) 146-150
69. Loftsson T., Gudmundsson J.A., Arnadottir R.O., and Fridriksdottir H. Sublingual delivery of 17beta-estradiol from cyclodextrin containing tablets. Pharmazie 58 (2003) 358-359
70. Price T.M., Blauer K.L., Hansen M., Stanczyk F., Lobo R., and Bates G.W. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol. Obstet. Gynecol. 89 (1997) 340-345
71. Miller B.E., De Souza M.J., Slade K., and Luciano A.A. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density. Menopause 7 (2000) 318-326
72. Gass M.S., Rebar R.W., Cuffie-Jackson C., Cedars M.I., Lobo R.A., Shoupe D., Judd H.L., Buyalos R.P., and Clisham P.R. A short study in the treatment of hot flashes with buccal administration of 17-beta estradiol. Maturitas 49 (2004) 140-147
73. Coelingh Bennink H.J. Are all estrogens the same?. Maturitas 47 (2004) 269-275
74. Ramachandran C., and Fleisher D. Transdermal delivery of drugs for the treatment of bone diseases. Adv. Drug Deliv. Rev. 42 (2000) 197-223
75. Chetkowski R.J., Meldrum D.R., Steingold K.A., Randle D., Lu J.K., Eggena P., Hershman J.M., Alkjaersig N.K., Fletcher A.P., and Judd H.L. Biologic effects of transdermal estradiol. N. Engl. J. Med. 314 (1986) 1615-1620
76. Crook D. The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. Br. J. Obstet. Gynaecol. 104 Suppl 16 (1997) 4-13
77. Geola F.L., Frumar A.M., Tataryn I.V., Lu K.H., Hershman J.M., Eggena P., Sambhi M.P., and Judd H.L. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J. Clin. Endocrinol. Metab. 51 (1980) 620-625
78. Selby P., McGarrigle H.H., and Peacock M. Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women. Clin. Endocrinol. (Oxf) 30 (1989) 241-249
79. Reginster J.Y., Albert A., Deroisy R., Colette J., Vrijens B., Blacker C., Brion N., Caulin F., Mayolle C., Regnard A., Scholler R., and Franchimont P. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50. Maturitas 27 (1997) 179-186
80. Sitruk-Ware R., de Lignieres B., Basdevant A., and Mauvais-Jarvis P. Absorption of percutaneous oestradiol in postmenopausal women. Maturitas 2 (1980) 207-211
81. Jarvinen A., Granander M., Nykanen S., Laine T., Geurts P., and Viitanen A. Steady-state pharmacokinetics of oestradiol gel in post-menopausal women: effects of application area and washing. Br. J. Obstet. Gynaecol. 104 Suppl 16 (1997) 14-18
82. Jarvinen A., Nykanen S., and Paasiniemi L. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 32 (1999) 103-113
83. Archer D.F. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause 10 (2003) 516-521
84. Powers M.S., Schenkel L., Darley P.E., Good W.R., Balestra J.C., and Place V.A. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am. J. Obstet. Gynecol. 152 (1985) 1099-1106
85. Corson S.L. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int. J. Fertil. 38 (1993) 79-91
86. Good W.R. A new transdermal delivery system for estradiol. J. Control. Release 2 (1985) 89-97
87. Youngkin E.Q. Estrogen replacement therapy and the estraderm transdermal system. Nurse Pract. 15 (1990) 19-26 (31)
88. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group. Int. J. Fertil. Menopausal Stud. 38 (1993) 5-11
89. Arrenbrecht S., and Boermans A.J. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial. Osteoporos. Int. 13 (2002) 176-183
90. De Aloysio D., Rovati L.C., Giacovelli G., Setnikar I., and Bottiglioni F. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study. Arzneimittelforschung 50 (2000) 293-300
91. Panay N., and Studd J.W. The psychotherapeutic effects of estrogens. Gynecol. Endocrinol. 12 (1998) 353-365
92. Studd J.W., Holland E.F., Leather A.T., and Smith R.N. The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women. Br. J. Obstet. Gynaecol. 101 (1994) 787-791
93. Gangar K., and Whitehead M.I. Hormone implants and tachyphylaxis. Br. J. Obstet. Gynaecol. 98 (1991) 607-609
94. Morgan T.M., O'Sullivan H.M., Reed B.L., and Finnin B.C. Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol. J. Pharm. Sci. 87 (1998) 1226-1228
95. David G.F., Puri C.P., and Anand Kumar T.C. Bioavailability of progesterone enhanced by intranasal spraying. Experientia 37 (1981) 533-534
96. Garnero P., Tsouderos Y., Marton I., Pelissier C., Varin C., and Delmas P.D. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J. Clin. Endocrinol. Metab. 84 (1999) 2390-2397
97. Hermens W.A., Belder C.W., Merkus J.M., Hooymans P.M., Verhoef J., and Merkus F.W. Intranasal estradiol administration to oophorectomized women. Eur. J. Obstet. Gynecol. Reprod. Biol. 40 (1991) 35-41
98. Hermens W.A., Belder C.W., Merkus J.M., Hooymans P.M., Verhoef J., and Merkus F.W. Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 43 (1992) 65-70
99. Rigg L.A., Milanes B., Villanueva B., and Yen S.S. Efficacy of intravaginal and intranasal administration of micronized estradiol-17beta. J. Clin. Endocrinol. Metab. 45 (1977) 1261-1264
100. Dooley M., Spencer C.M., and Ormrod D. Estradiol-intranasal: a review of its use in the management of menopause. Drugs 61 (2001) 2243-2262
101. Devissaguet J.P., Brion N., Lhote O., and Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur. J. Drug. Metab. Pharmacokinet. 24 (1999) 265-271
102. Lopes P., Merkus H.M., Nauman J., Bruschi F., Foidart J.M., and Calaf J. Randomized comparison of intranasal and transdermal estradiol. Obstet. Gynecol. 96 (2000) 906-912
103. Studd J., Pornel B., Marton I., Bringer J., Varin C., Tsouderos Y., and Christiansen C. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol. Study Group. Lancet 353 (1999) 1574-1578
104. Diel P., Laudenbach-Leschowsky U., Friedel A., Voss A., and Roussel J. Pulsed estradiol exposure has a limited ability to induce uterine proliferation in ovariectomised female Wistar rats. Mol. Cell. Endocrinol. 230 (2005) 7-15
105. Mattsson L.A., Christiansen C., Colau J.C., Palacios S., Kenemans P., Bergeron C., Chevallier O., Von Holst T., and Gangar K. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Am. J. Obstet. Gynecol. 182 (2000) 545-552
106. Delmas P.D., Marianowski L., Perez Ade C., Ribot C., Pornel B., Palacios S., and Lopes P. Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route. Maturitas 48 (2004) 85-96
107. Nielsen T.F., Ravn P., Bagger Y.Z., Warming L., and Christiansen C. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study. Osteoporos. Int. 15 (2004) 168-174
108. Richards Grayson A.C., Choi I.S., Tyler B.M., Wang P.P., Brem H., Cima M.J., and Langer R. Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat. Mater. 2 (2003) 767-772
109. Bawarshi-Nassar R.N., Hussain A.A., and Crooks P.A. Nasal absorption and metabolism of progesterone and 17 beta-estradiol in the rat. Drug Metab. Dispos. 17 (1989) 248-254
110. Cicinelli E., Ragno G., Cagnazzo I., Fanelli F., Vetuschi C., and Schonauer S. Progesterone administration by nasal spray. Fertil. Steril. 56 (1991) 139-141
111. Schipper N., Hermens W., Romeyn S., Verhoef J., and Merkus F. Nasal absorption of 17-beta-estradiol and progesterone from a dimethyl-cyclodextrin inclusion formulation in rats. Int. J. Pharm. 64 (1990) 61-66
112. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet. Gynecol. 102 (2003) 823-834
113. Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 65 (2000) 699-702
114. Willhite L.A., and O'Connell M.B. Urogenital atrophy: prevention and treatment. Pharmacotherapy 21 (2001) 464-480
115. Ballagh S.A. Vaginal hormone therapy for urogenital and menopausal symptoms. Semin. Reprod. Med. 23 (2005) 126-140
116. Nilsson K., and Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency-A pharmacokinetic and pharmacodynamic study. Maturitas 15 (1992) 121-127
117. Rigg L.A., Hermann H., and Yen S.S. Absorption of estrogens from vaginal creams. N. Engl. J. Med. 298 (1978) 195-197
118. Weisberg E., Ayton R., Darling G., Farrell E., Murkies A., O'Neill S., Kirkegard Y., and Fraser I.S. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 8 (2005) 83-92
119. Naessen T., Rodriguez-Macias K., and Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J. Clin. Endocrinol. Metab. 86 (2001) 2757-2762
120. Prestwood K.M., Kenny A.M., Kleppinger A., and Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 290 (2003) 1042-1048
121. Mandel F.P., Geola F.L., Meldrum D.R., Lu J.H., Eggena P., Sambhi M.P., Hershman J.M., and Judd H.L. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J. Clin. Endocrinol. Metab. 57 (1983) 133-139
122. Barentsen R., van de Weijer P.H., and Schram J.H. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur. J. Obstet. Gynecol. Reprod. Biol. 71 (1997) 73-80
123. Hamada A.L., Maruo T., Samoto T., Yoshida S., Nash H., Spitz I.M., and Johansson E. Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. Gynecol. Endocrinol. 17 (2003) 247-254
124. Heimer G., and Englund D. Estriol: absorption after long-term vaginal treatment and gastrointestinal absorption as influenced by a meal. Acta Obstet. Gynecol. Scand. 63 (1984) 563-567
125. Henriksson L., Stjernquist M., Boquist L., Alander U., and Selinus I. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am. J. Obstet. Gynecol. 171 (1994) 624-632
126. Levine H., and Watson N. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women (3). Fertil. Steril. 73 (2000) 516-521
127. Rioux J.E., Devlin C., Gelfand M.M., Steinberg W.M., and Hepburn D.S. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7 (2000) 156-161
128. Buckshee K., Kumar S., and Saraya L. Contraceptive vaginal ring-a rising star on the contraceptive horizon. Adv. Contracep. 6 (1990) 177-183
129. Dezarnaulds G., and Fraser I.S. Vaginal ring delivery of hormone replacement therapy-A review. Expert Opin. Pharmacother. 4 (2003) 201-212
130. Englund D.E., Victor A., and Johansson E.D. Pharmacokinetics and pharmacodynamic effects of vaginal oestradiol administration from silastic rings in post-menopausal women. Maturitas 3 (1981) 125-133
131. Nash H.A., Alvarez-Sanchez F., Mishell Jr. D.R., Fraser I.S., Maruo T., and Harmon T.M. Estradiol-delivering vaginal rings for hormone replacement therapy. Am. J. Obstet. Gynecol. 181 (1999) 1400-1406
132. Roumen F.J., and Dieben T.O. Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. Contraception 59 (1999) 59-62
133. Stumpf P.G. Selecting constant serum estradiol levels achieved by vaginal rings. Obstet. Gynecol. 67 (1986) 91-94
134. Stumpf P.G., Maruca J., Santen R.J., and Demers L.M. Development of a vaginal ring for achieving physiologic levels of 17 beta-estradiol in hypoestrogenic women. J. Clin. Endocrinol. Metab. 54 (1982) 208-210
135. Vartiainen J., Wahlstrom T., and Nilsson C.G. Effects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas 17 (1993) 129-137
136. Weisberg E., Fraser I.S., Mishell Jr. D.R., Lacarra M., Darney P., and Jackanicz T.M. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception 59 (1999) 305-310
137. Lee C.H., and Chien Y.W. Drug delivery, vaginal route. In: Swarbrick J., and Boylan J.C. (Eds). Encyclopedia of Pharmaceutical Technology (2002), Marcel Dekker, New York 961-985
138. Johansson E.D., and Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am. J. Obstet. Gynecol. 190 (2004) S54-S59